Education
About Us
Working with TipRanks
Follow Us
Keros Therapeutics (KROS)
NASDAQ:KROS
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 3.55M | $ 151.00K | $ 0.00 | $ 20.10M | $ 0.00 |
| Gross Profit | $ 3.55M | $ -664.00K | $ -1.61M | $ 19.20M | $ -605.00K |
| Operating Income | $ -210.83M | $ -169.94M | $ -114.79M | $ -56.37M | $ -46.66M |
| EBITDA | $ -185.82M | $ -152.18M | $ -103.06M | $ -56.37M | $ -44.92M |
| Net Income | $ -187.35M | $ -152.99M | $ -104.68M | $ -58.74M | $ -45.36M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 559.93M | $ 331.15M | $ 279.05M | $ 230.04M | $ 265.88M |
| Total Assets | $ 615.89M | $ 370.02M | $ 306.78M | $ 255.25M | $ 269.44M |
| Total Debt | $ 18.86M | $ 14.44M | $ 13.27M | $ 1.09M | $ 899.00K |
| Net Debt | $ -541.07M | $ -316.70M | $ -265.78M | $ -228.95M | $ -264.98M |
| Total Liabilities | $ 44.33M | $ 37.81M | $ 29.36M | $ 12.08M | $ 7.72M |
| Stockholders' Equity | $ 571.55M | $ 332.21M | $ 277.42M | $ 243.17M | $ 261.72M |
| Cash Flow | |||||
| Free Cash Flow | $ -162.80M | $ -126.97M | $ -71.30M | $ -63.17M | $ -37.19M |
| Operating Cash Flow | $ -160.87M | $ -124.51M | $ -70.06M | $ -62.15M | $ -36.89M |
| Investing Cash Flow | $ -1.93M | $ -2.46M | $ -1.24M | $ -1.02M | $ -294.00K |
| Financing Cash Flow | $ 391.82M | $ 178.96M | $ 120.31M | $ 28.55M | $ 296.04M |